



Controversies in Ophthalmology

[Home](#)

[Registration](#)

[Accommodation](#)

[Topics](#)

[Contact](#)

[Home](#)

[Welcome Note](#)

[Committees](#)

[List of Faculty](#)

[Speaker Guidelines](#)

[Timetable](#)

[Scientific Program](#)

[Anterior Segment Section](#)

[Glaucoma Section](#)

[Retina Section](#)

[Neuro-Ophthalmology](#)

[Trauma](#)

[Uveitis](#)

[New Plays in the Game](#)

[Symposia](#)

[Poster Presentations](#)

[Group A](#)

[Group B](#)

[Poster Presentation Guidelines](#)

[Registration](#)

[Invitation Letter](#)

[Accommodation](#)

[InterContinental Budapest](#)

[Sponsorship & Exhibition](#)

[Sponsors](#)

[Exhibitors](#)

[CME](#)

[General Information](#)

[Local Agent](#)

[Italian Agent](#)

[Before you travel...](#)

[About Budapest](#)

[Endorsements](#)

[Partners](#)

[Previous Congresses](#)

[COPHy 2010](#)

[COPHy 2011](#)

[COPHy 2012](#)



The 4th World Congress on
CONTROVERSIES IN OPHTHALMOLOGY (COPHY)
Anterior Segment, Glaucoma, Retina
BUDAPEST, HUNGARY • APRIL 4 - 7, 2013

Neuro-Ophthalmology



Please click on the session title to review a summary of the topics to be discussed

Friday, April 5, 2013

Neuro-Ophthalmology I
16:45-18:15

Moderators: **A. Kesler**, Israel; **A. Lee**, USA

16:45-17:10 **Debate: Is there any treatment for NAION?**

- a) Steroids: **A. Lee**, USA
- b) Hemodilution: **J. Somlai**, Hungary
- c) Intravitreal bevacizumab/ranibizumab : **A. Arnold**, USA
- d) Erythropoietin: **N. Miller**, USA
- e) Electrophysiological methods for evaluation of subclinical functional abnormalities in the visual pathway in patients with type I diabetes mellitus: **M. Janaky**, Hungary
- f) Conclusion: **A. Kesler**, Israel; **M. Janaky**, Hungary and **A. Lee**, USA

17:10-17:55 **Debate: Pseudotumor cerebri, idiopathic intracranial hypertension and venous sinus stenosis**

- 1) In a patient with typical IIH, do you get an MRV?
 - a) Yes: **S. Tow**, Singapore
 - b) No: **A. Arnold**, USA
- 2) If the MRV shows VST, how do you treat the patients?
 - a) If the patient has moderate papilledema but no optic neuropathy
 - 1) Medical stenting: **A. Kesler**, Israel
 - 2) Stenting: **N. Miller**, USA
 - b) If the patient has moderate papilledema with evidence of an optic neuropathy
 - 1) Medical therapy: **J. Somlai**, Hungary
 - 2) Non-stent surgery (eg, ONSF, shunt): **A. Arnold**, USA
 - 3) Stenting: **A. Lee**, USA
 - c) For those who stent, does your decision depend on what happens after you lower ICP?
 - 1) Yes: **N. Miller**, USA
 - 2) No: **A. Lee**, USA
 - d) For those who stent, does it matter if there is a gradient?
 - 1) Yes: **N. Miller**, USA
 - 2) No: **A. Arnold**, USA
 - e) Conclusion: **A. Kesler**, Israel; **M. Janaky**, Hungary and **A. Lee**, USA

17:55-18:15 **Case presentations**

Moderator: **N. Miller**, USA

- 1) Child with congenital nystagmus (classification and treatment options)
A. Kesler, Israel
- 2) Older adult with isolated esotropia and abduction weakness
A. Lee, USA
- 3) Young adult woman with acute optic neuritis (initial eval, treatment; recurrence issue)
A. Arnold, USA and **S. Tow**, Singapore
- 4) Young adult woman with bilateral steroid-sensitive, steroid-dependent optic neuritis
J. Somlai, Hungary
- 5) Older adult with acute CRAO
A. Arnold, USA
- 6) Young man with LHON (as well as patient's asymptomatic brother)
A. Lee, USA

7) Elderly woman with acute diplopia, scalp tenderness, and fatigue
A. Kesler, Israel and **A. Lee**, USA

Saturday, April 6, 2013

Neuro-Ophthalmology II
16:30-18:00

Moderators: **A. Arnold**, USA; **J. Somlai**, Hungary

16:30-16:50 **Is there any treatment for traumatic optic neuropathy?**

- a) Steroids (including how much): **J. Somlai**, Hungary
 - b) Treat with surgery (immediately? After steroids? After time?): **A. Arnold**, USA
 - c) Other: **N. Miller**, USA
 - d) There is no treatment: **S. Tow**, Singapore
- 3) Conclusions: **A. Arnold**, USA; **M. Janaky**, Hungary and **J. Somlai**, Hungary

16:50-17:10 **What is the optimum treatment for ocular myasthenia gravis?**

- a) Mestinon: **A. Kesler**, Israel
- b) Systemic steroids: **A. Lee**, USA
- c) Non-steroidal immunosuppressive agent (eg, Cellcept, Imuran) (with or without steroids): **J. Somlai**, Hungary
- d) Conclusions: **A. Arnold**, USA; **M. Janaky**, Hungary and **J. Somlai**, Hungary

17:10-18:00 **Case presentations**

Moderator: **N. Miller**, USA

- 1) A child with chiasmal glioma
A. Arnold, USA; **A. Kesler**, Israel and **S. Tow**, Singapore
- 2) A young adult with NAION
A. Kesler, Israel
- 3) An older adult with NAION on amiodarone
A. Lee, USA
- 4) An older adult with NAION who used an erectile dysfunction drug the night before
A. Arnold, USA
- 5) An older adult with NAION and obstructive sleep apnea
A. Kesler, Israel
- 6) An older adult with recurrent NAION
J. Somlai, Hungary
- 7) Threshold for treating a middle-aged woman with a presumed optic nerve sheath meningioma
A. Lee, USA
- 8) A child with Horner syndrome
A. Kesler, Israel; **A. Arnold**, USA and **S. Tow**, Singapore

[Home](#)